Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

Airways inflammation is thought to play a central role in the pathogenesis of asthma. However, the precise role that individual inflammatory cells and mediators play in the development of airways hyperreactivity and the morphological changes of the lung during allergic pulmonary inflammation is unknown. In this investigation we have used a mouse model of allergic pulmonary inflammation and interleukin (IL) 5-deficient mice to establish the essential role of this cytokine and eosinophils in the initiation of aeroallergen-induced lung damage and the development of airways hyperreactivity. Sensitization and aerosol challenge of mice with ovalbumin results in airways eosinophilia and extensive lung damage analogous to that seen in asthma. Aeroallergen-challenged mice also display airways hyperreactivity to beta-methacholine. In IL-5-deficient mice, the eosinophilia, lung damage, and airways hyperreactivity normally resulting from aeroallergen challenge were abolished. Reconstitution of IL-5 production with recombinant vaccinia viruses engineered to express this factor completely restored aeroallergen-induced eosinophilia and airways dysfunction. These results indicate that IL-5 and eosinophils are central mediators in the pathogenesis of allergic lung disease.

[1]  P. Hodgkin,et al.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. , 1996, Immunity.

[2]  Hongyung Choi,et al.  IgE and eosinophil regulation in a murine model of allergic aspergillosis , 1994, Journal of leukocyte biology.

[3]  A. Husband,et al.  The role of interleukin-6 in mucosal IgA antibody responses in vivo. , 1994, Science.

[4]  J. Hsuan,et al.  Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation , 1994, The Journal of experimental medicine.

[5]  J. Tavernier,et al.  Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion , 1994, The Journal of experimental medicine.

[6]  P. Weller,et al.  Eosinophils: structure and functions. , 1994, Current opinion in immunology.

[7]  A. Minty,et al.  Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine , 1994, The Journal of experimental medicine.

[8]  R. Pauwels,et al.  Attenuation of allergic airway inflammation in IL‐4 deficient mice , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  L. Lichtenstein,et al.  Immunological aspects of allergic asthma. , 1994, Annual review of immunology.

[10]  M. Kohonen-Corish,et al.  Interleukin‐5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo , 1993, European journal of immunology.

[11]  R. Egan,et al.  Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. , 1993, The American review of respiratory disease.

[12]  P. Weller,et al.  Mechanisms of eosinophil recruitment. , 1993, American journal of respiratory cell and molecular biology.

[13]  H. Nagai,et al.  Effect of murine recombinant interleukin‐5 on bronchial reactivity in guinea‐pigs , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  T. Schall,et al.  RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes , 1992, The Journal of experimental medicine.

[15]  J. Virchow,et al.  Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. , 1992, The American review of respiratory disease.

[16]  T. Fukuda,et al.  Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. , 1992, The American review of respiratory disease.

[17]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[18]  K. Blaser,et al.  Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. , 1991, The Journal of allergy and clinical immunology.

[19]  D. Broide,et al.  Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. , 1991, The Journal of allergy and clinical immunology.

[20]  A J Wardlaw,et al.  Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. , 1991, The Journal of clinical investigation.

[21]  J. Virchow,et al.  T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. , 1991, Journal of immunology.

[22]  A. Kay,et al.  Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. , 1991, The American review of respiratory disease.

[23]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[24]  B. Wiggs,et al.  Inhibition of antigen-induced airway hyperresponsiveness, but not acute hypoxia nor airway eosinophilia, by an antagonist of platelet-activating factor. , 1990, Journal of immunology.

[25]  H. Reynolds,et al.  Macrophages and polymorphonuclear neutrophils in lung defense and injury. , 1990, The American review of respiratory disease.

[26]  R. Coffman,et al.  Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. , 1989, Science.

[27]  S. Holgate,et al.  Cellular events in the bronchi in mild asthma and after bronchial provocation. , 1989, The American review of respiratory disease.

[28]  N. Flavahan,et al.  The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. , 1988, The Journal of allergy and clinical immunology.

[29]  T. Suda,et al.  Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor , 1988, The Journal of experimental medicine.

[30]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[31]  A. Wardlaw,et al.  Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. , 1988, The American review of respiratory disease.

[32]  I. G. Young,et al.  Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.